Sanofi and Regeneron Report Results of REGN3500 in P-II Study for Asthma

Sanofi and Regeneron Report Results of REGN3500 in P-II Study for Asthma

Shots:

  • The P-II study results involve assessing of REGN3500 + PBO, REGN3500 + Dupixent, Dupixent + PBO and PBO in 296 patients with moderate-to-severe asthma who were not well controlled on LABA and ICS therapy for 12wks.
  • The P-II study resulted in meeting its 1EPs & 2EPs i.e, improvement in loss of asthma control & improvement in lung function respectively
  • REGN3500 (SAR440340) is a mAb, inhibiting IL-33, being evaluated in P-II studies for asthma, chronic obstructive pulmonary disease and atopic dermatitis, invented utilizing Regeneron’s VelocImmune technology, co-developed by Sanofi & Regeneron

Click here to read full press release/ article | Ref: Sanofi | Image: Stat